Hangzhou Tigermed Consulting Co (HKSE:03347) Ending Cash Position : HK$1,597 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Ending Cash Position?

Hangzhou Tigermed Consulting Co's Ending Cash Position for the quarter that ended in Mar. 2025 was HK$1,597 Mil.

Hangzhou Tigermed Consulting Co's quarterly Ending Cash Position increased from Sep. 2024 (HK$2,160 Mil) to Dec. 2024 (HK$2,187 Mil) but then declined from Dec. 2024 (HK$2,187 Mil) to Mar. 2025 (HK$1,597 Mil).

Hangzhou Tigermed Consulting Co's annual Ending Cash Position declined from Dec. 2022 (HK$8,691 Mil) to Dec. 2023 (HK$8,094 Mil) and declined from Dec. 2023 (HK$8,094 Mil) to Dec. 2024 (HK$2,187 Mil).

Hangzhou Tigermed Consulting Co Ending Cash Position Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co Ending Cash Position Chart

Hangzhou Tigermed Consulting Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

11,806.87

10,259.10

8,691.10

8,093.90

2,187.12

Hangzhou Tigermed Consulting Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															8,062.29	3,405.26	2,160.13	2,187.12	1,597.23

Hangzhou Tigermed Consulting Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hangzhou Tigermed Consulting Co's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	7900.711	+	-5713.591
	=	2,187

Hangzhou Tigermed Consulting Co's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2196.424	+	-599.197
	=	1,597

Hangzhou Tigermed Consulting Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

5HZ1:Germany 300347:China

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Executives

Sands Capital Management, Llc	2101 Beneficial owner
Sands Capital Management, Lp	2201 Interest of corporation controlled by you
Sands Family Trust, Llc	2201 Interest of corporation controlled by you
Sands Frank Melville Jr.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
F-j Sands Family I, Llc	2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd	2102 Investment manager
Ninety One Uk Limited	2102 Investment manager
Baillie Gifford & Co	2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines